Alice Valder Curran joined the Pharmaceutical Executive Podcast to discuss the ongoing strategizing for MFN pricing in the pharma industry. With the launch of TrumpRx, the industry has a better idea of what the administration is looking for in negotiations. However, recent tariff rulings could impact the primary way the administration has enforced its position in negotiations.
- MFN pricing is still evolving as comments are due on the proposed rules for the globe and guard model.
- Manufacturers have long had processes for providing price reductions to patients, including paper coupons and co-pay assistance cards.
- MFN may prevent some companies from launching drugs in global markets if they can’t make the pricing work with MFN pricing in the US.
- The Supreme Court’s decision on tariffs was on IEEPA tariffs, while the administration's MFN negotiations involve section 232 tariffs.
